FI63494C - Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod - Google Patents

Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod Download PDF

Info

Publication number
FI63494C
FI63494C FI763446A FI763446A FI63494C FI 63494 C FI63494 C FI 63494C FI 763446 A FI763446 A FI 763446A FI 763446 A FI763446 A FI 763446A FI 63494 C FI63494 C FI 63494C
Authority
FI
Finland
Prior art keywords
factor
activity
sulphate
polysaccharide
xal
Prior art date
Application number
FI763446A
Other languages
English (en)
Finnish (fi)
Other versions
FI63494B (fi
FI763446A (nl
Inventor
Ee Thye Yin
Oddvar Tangen
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI763446A publication Critical patent/FI763446A/fi
Publication of FI63494B publication Critical patent/FI63494B/fi
Application granted granted Critical
Publication of FI63494C publication Critical patent/FI63494C/fi

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96444—Factor X (3.4.21.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI763446A 1975-12-01 1976-11-30 Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod FI63494C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE7513495 1975-12-01
SE7513495A SE419871B (sv) 1975-12-01 1975-12-01 Sett att bestemma aktiviteten hos faktor xa-inhibitor i blod

Publications (3)

Publication Number Publication Date
FI763446A FI763446A (nl) 1977-06-02
FI63494B FI63494B (fi) 1983-02-28
FI63494C true FI63494C (fi) 1983-06-10

Family

ID=20326201

Family Applications (1)

Application Number Title Priority Date Filing Date
FI763446A FI63494C (fi) 1975-12-01 1976-11-30 Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod

Country Status (15)

Country Link
US (1) US4139415A (nl)
JP (1) JPS5915640B2 (nl)
AT (1) AT348687B (nl)
AU (1) AU508343B2 (nl)
BE (1) BE848932A (nl)
CA (1) CA1060324A (nl)
CH (1) CH625052A5 (nl)
DE (1) DE2654189C3 (nl)
DK (1) DK537676A (nl)
FI (1) FI63494C (nl)
FR (1) FR2334109A1 (nl)
GB (1) GB1562808A (nl)
NL (1) NL7613376A (nl)
NO (1) NO148960C (nl)
SE (1) SE419871B (nl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2757992A1 (de) * 1977-12-24 1979-06-28 Boehringer Mannheim Gmbh Verfahren zur prothrombin-bestimmung
US4302538A (en) * 1978-03-27 1981-11-24 Ortho Diagnostics Inc. Buffer system in an anti-thrombin III test
SE422081B (sv) * 1979-08-22 1982-02-15 Ird Biomaterial Ab Sett att pavisa proteolytiska enzymer
CA1161432A (en) * 1980-02-12 1984-01-31 Lars G. Svendsen Tripeptide derivatives and their application in assaying enzymes
EP0049877B1 (de) * 1980-10-09 1984-05-23 Roche Diagnostics GmbH Verfahren und Reagenz zur Bestimmung von Antithrombin-BM
US4753875A (en) * 1981-11-02 1988-06-28 Ryan James W Method for assaying proteases with tagged proteinaceous inhibitors
US5221614A (en) * 1988-03-03 1993-06-22 Nippon Shoji Kabushiki Kaisha Method and reagent for determining the biological activity of antithrombin III by measuring coagulation time
GB9602166D0 (en) * 1996-02-02 1996-04-03 Zeneca Ltd Aminoheterocyclic derivatives
DE19634312A1 (de) * 1996-08-24 1998-02-26 Behringwerke Ag Verfahren zur Herstellung von Faktor V-Mangelplasma und ein so erhaltenes Mangelplasma
US6432658B1 (en) 2000-09-13 2002-08-13 Affinity Biologicals, Inc. Method for measuring antithrombin activity
EP2818871A1 (en) * 2013-06-28 2014-12-31 Roche Diagniostics GmbH Means and methods for universal calibration of anti-Factor Xa tests

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE380257B (sv) * 1972-05-02 1975-11-03 Bofors Ab Nya diagnostiskt verksamma substrat med hog specificitet till trombin och andra proteolytiska enzymer av typen peptidyl-peptid-hydrolaser
US3985618A (en) * 1975-05-02 1976-10-12 Irving Innerfield Method for detection of thrombosis and prethrombosis

Also Published As

Publication number Publication date
DK537676A (da) 1977-06-02
AU2006176A (en) 1978-06-08
BE848932A (fr) 1977-05-31
FR2334109A1 (fr) 1977-07-01
ATA891076A (de) 1978-07-15
CH625052A5 (nl) 1981-08-31
NO764081L (nl) 1977-06-02
FR2334109B1 (nl) 1982-03-12
DE2654189A1 (de) 1977-06-08
FI63494B (fi) 1983-02-28
DE2654189C3 (de) 1985-10-03
JPS5297792A (en) 1977-08-16
AU508343B2 (en) 1980-03-20
NL7613376A (nl) 1977-06-03
FI763446A (nl) 1977-06-02
GB1562808A (en) 1980-03-19
NO148960B (no) 1983-10-10
SE7513495L (sv) 1977-06-02
AT348687B (de) 1979-02-26
DE2654189B2 (de) 1979-03-08
JPS5915640B2 (ja) 1984-04-10
CA1060324A (en) 1979-08-14
NO148960C (no) 1984-01-18
SE419871B (sv) 1981-08-31
US4139415A (en) 1979-02-13

Similar Documents

Publication Publication Date Title
Andersson et al. Molecular weight dependency of the heparin potentiated inhibition of thrombin and activated factor X. Effect of heparin neutralization in plasma
US6756208B2 (en) Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
FI63494C (fi) Foerfarande foer in vitro-bestaemning av faktor xa-inhibitor iblod
EP0203509B1 (de) Verfahren zur quantitativen Bestimmung von Protein C und Aktivatorpräparat zur Durchführung des Verfahrens
AU2003204479A1 (en) A pharmaceutical preparation for treating blood coagulation disorders
CZ78693A3 (en) Pharmaceutical preparation for treating prolongated coagulation period
FI64466B (fi) Foerfarande och reagens foer bestaemning av protrombin
Thomsen et al. Immunohistochemical detection of C5b-9 (m) in myocardium: an aid in distinguishing infarction-induced ischemic heart muscle necrosis from other forms of lethal myocardial injury
Pabinger-Fasching et al. High levels of plasma protein C in nephrotic syndrome
EP1230382B1 (en) Monitoring the activity of factor xa inhibitors
Matsuda et al. Selective determination of α2-plasmin inhibitor activity in plasma using chromogenic substrate
US4882272A (en) High molecular weight kininogen assay
Sie et al. Inactivation of heparin cofactor II by polymorphonuclear leukocytes
Fischer et al. Comparison between the effect of pentosan polysulphate heparin and antithrombin III injections in antithrombin III deficient patients
Grau et al. Plasma and urinary heparin cofactor II levels in patients with nephrotic syndrome
Wages et al. Structural characterization and functional effects of a circulating heparan sulfate in a patient with hepatocellular carcinoma
Nigretto et al. Contributions of negatively charged chemical groups to the surface-dependent activation of human plasma by soluble dextran derivatives
Hemkera Development of a rapid and sensitive chromogenic heparin assay for clinical use
CS226407B2 (en) Method of determining mb creatinkinase
Palmer et al. Inhibition of the cold activation of factor VII and the prothrombin time
Baruch et al. Inhibition of thrombin-catalyzed reactions in blood coagulation and platelet activation by heparin fractions in the absence of antithrombin III
Kleniewski et al. Some molecular and functional changes in high molecular weight kininogen induced by plasmin and trypsin
Van den Besselaar et al. Response of the activated partial thromboplastin time (APTT) to heparin is influenced by coagulometers
Nakhleh et al. Heparin cofactor II assay: elimination of heparin and antithrombin-III effects
Koller Physiology and Pathology of Blood Coagulation

Legal Events

Date Code Title Description
MM Patent lapsed

Owner name: PHARMACIA AB